Pharmacology News and Research

Latest Pharmacology News and Research

Research aims to reduce scarring from heart attacks

A heart damaged by heart attack is usually broken, at least partially, for good.

14 Dec 2008

Postmenopausal patients being considered for tamoxifen therapy should be tested for CYP2D6 gene deficiency

Findings from a new study have prompted Mayo Clinic researchers to recommend CYP2D6 gene testing for postmenopausal women about to begin tamoxifen therapy.

14 Dec 2008

Study shows major pain research funding decline at NIH

Federal funding for pain research is declining sharply, more than 9 percent a year since 2003, according to a new study published in The Journal of Pain.

12 Dec 2008

Cellular 'brakes' may slow memory process in aging brains

University of Florida researchers may have discovered why some brain cells necessary for healthy memory can survive old age or disease, while similar cells hardly a hairsbreadth away die.

10 Dec 2008

Intradigm issued new RNAi therapeutics patent

Intradigm Corporation has announced the issuance of United States patent 7,459,547, entitled "Methods and Compositions for Controlling Efficacy of RNA Silencing."

3 Dec 2008

More evidence on why the Mediterranean diet is good for heart

Researchers have discovered one potential mechanism by which briefly cutting off, then restoring, blood flow to arteries prior to a heart attack lessens the damage caused, according to a study published today in the journal Cardiovascular Research.

2 Dec 2008

Researchers find clue to safer obesity drugs

Once hailed as a miracle weight-loss drug, Fen-phen was removed from the market more than a decade ago for inducing life-threatening side effects, including heart valve lesions. Scientists at UT Southwestern Medical Center are trying to understand how Fen-phen behaves in the brain in order to develop safer anti-obesity drugs with fewer side effects.

25 Nov 2008

Researchers develop new strategy for broad spectrum anti-viral drugs

Bavituximab, an anti-viral drug developed by UT Southwestern Medical Center researchers, shows promise as a new strategy to fight viral diseases, including potential bioterrorism agents.

24 Nov 2008

Discovery of novel drug target for chronic lymphocytic leukemia

Researchers at the University of California, San Diego (UCSD) and the Moores UCSD Cancer Center have discovered what could be a novel drug target for an often difficult-to-treat form of leukemia.

24 Nov 2008

Strong link between antidepressants fluoxetine and paroxetine and heart anomalies in pregnancy

Women who took the antidepressant fluoxetine during the first three months of pregnancy gave birth to four times as many babies with heart problems as women who did not and the levels were three times higher in women taking paroxetine.

24 Nov 2008

Pregnancy study finds strong association between two antidepressants and heart anomalies

24 Nov 2008

Lactic acid found to be important energy source for tumor cells

Many tumors have cells that burn fuel for activities in different ways. Tumor cells near blood vessels have adequate oxygen sources and can either burn glucose like normal cells, or lactic acid (lactate). Tumor cells further from vessels are hypoxic and inefficiently burn a lot of glucose to keep going. In turn, they produce lactate as a waste product.

20 Nov 2008

New compounds break up cancer-causing protein STAT3 and destroy breast cancer tumors.

Two new compounds created by a University of Central Florida professor show early promise for destroying breast cancer tumors.

19 Nov 2008

Nontoxic nanoparticle delivers and tracks drugs

A nontoxic nanoparticle developed by Penn State researchers is proving to be an all-around effective delivery system for both therapeutic drugs and the fluorescent dyes that can track their delivery.

18 Nov 2008

Ginkgo's benefits for cognitive decline treatment supported by scientific research

A vast body of research supports numerous health benefits for ginkgo extracts, particularly for treating various symptoms and conditions associated with declining cognitive performance and poor circulation, says the American Botanical Council, an independent nonprofit research and education organization.

18 Nov 2008

A link found between nicotine addiction and autism

Scientists have identified a relationship between two proteins in the brain that has links to both nicotine addiction and autism.

17 Nov 2008

Breakthrough reveals first ever complete structure of a nuclear hormone receptor on human DNA

For decades, scientists have been studying nuclear hormone receptors to gain a better understanding of how they turn genes on and off throughout the body and how they function as key drug targets for a number of diseases, such as diabetes, breast cancer, osteoporosis and high cholesterol. A new UVA Health System study, led by Fraydoon Rastinejad, Ph.D., professor of pharmacology and director of the UVA Center for Molecular Design and published in the October 29 issue of Nature, reveals the first ever complete structure of a nuclear hormone receptor on human DNA – a discovery that now clears a new path for scientists to design more effective drugs with fewer associated health risks. “Dr. Rastinejad’s findings fundamentally change the way people all over the world will study how nuclear hormone receptors work and introduces a new platform for designing better drugs,” says Jim Garrison, Ph.D., professor of pharmacology at UVA Health System. Nuclear hormone receptors, including the peroxisome proliferator-activated receptors (PPARs), are proteins that sit on the surface of cells and bind to specific hormones such as estrogen, progesterone and thyroid hormone. Once the receptor binds to its hormone and its DNA regulatory element, it can cause a number of alterations in the cell, switching genes on and off. These switches control the continual regulation of the metabolic system and reproductive tissues, as well as the development and differentiation of skin, bone and behavioral centers in the brain. “PPARs are widely studied because they regulate the genes that produce fat cells, glucose, insulin, lipids and metabolism,” says Dr. Rastinejad. “That’s what makes them such good drug targets for diseases like diabetes. We can design drugs more rationally to bind to the PPAR nuclear receptor complex to help regulate these functions in the body.” A number of diabetes drugs, called insulin sensitizers, have been developed based on that knowledge, but now that scientists have a clear view into how these receptors bind and what shape they take the door is wide open for the development of better drugs. "After 40 years of nuclear receptor research, we finally can view the first full and complete structure of a nuclear receptor, thanks to Dr. Rastinejad’s break-though achievement,” says Bert W. O’Malley, Ph.D., professor and chairman, Department of Molecular and Cellular Biology at Baylor College of Medicine who is widely considered a top expert in the field.

17 Nov 2008